# A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

> **NCT06003426** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 1255 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** BMS-986278
- **DRUG:** BMS-986278 Placebo

## Key facts

- **NCT ID:** NCT06003426
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-14
- **Primary completion:** 2026-10-06
- **Final completion:** 2027-06-04
- **Target enrollment:** 1255 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06003426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06003426, "A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06003426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*